Search results for "Hormonal"

showing 10 items of 136 documents

Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma: 12-year results of a phase II study

2003

OBJECTIVE To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2–4N0–3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an objective…

medicine.medical_specialtyPerformance statusmedicine.drug_classbusiness.industryUrologyUrologyAntiandrogenmedicine.diseaseSurgeryFlutamideProstate-specific antigenchemistry.chemical_compoundProstate cancerchemistrymedicineCarcinomaHormonal therapymedicine.symptomBone painbusinessBJU International
researchProduct

Progestogens reduce thromboxane production by cultured human endothelial cells.

2011

Objectives Progestogens have been poorly studied concerning their roles in endothelial physiology. Prostanoids are vasoactive compounds, such as thromboxane A2, a potent vasoconstrictor, and prostacyclin, a vasodilator. We examined the effects of two progestogens used clinically, progesterone and medroxyprogesterone acetate, on thromboxane A2 production by cultured human umbilical vein endothelial cells (HUVEC) and investigated the role of progesterone receptors and the enzymes involved in production of thromboxane A2 and prostacyclin. Methods Cells were exposed to 1‐100 nmol/l of either progesterone or medroxyprogesterone acetate, and thromboxane A2 production was measured in culture mediu…

medicine.medical_specialtyUmbilical VeinsAntineoplastic Agents HormonalThromboxaneBlotting WesternGene ExpressionProstacyclinMedroxyprogesterone AcetatePolymerase Chain ReactionProstacyclin synthaseThromboxane receptorThromboxane ProductionThromboxane A2chemistry.chemical_compoundThromboxane A2Hormone AntagonistsCytochrome P-450 Enzyme SystemInternal medicineProgesterone receptorMedicineHumansCyclooxygenase InhibitorsRNA MessengerCells CulturedProgesteronebiologyDose-Response Relationship Drugbusiness.industryObstetrics and GynecologyEndothelial CellsGeneral MedicineIntramolecular OxidoreductasesThromboxane B2MifepristoneEndocrinologychemistrycardiovascular systembiology.proteinPyrazolesThromboxane-A synthaseThromboxane-A SynthaseProgestinsbusinessmedicine.drugClimacteric : the journal of the International Menopause Society
researchProduct

Efficacy and tolerability of a plant-based, multi-component cream (Ginetrox®) in vulvovaginal disorders of the genitourinary syndrome during menopaus…

2017

BACKGROUND Genitourinary syndrome of menopause (GSM) is a symptomatic condition including vaginal dryness, irritation, dyspareunia and recurrent urinary tract infections which affects 40-54% of post-menopausal women. Although several estrogen-based therapies are available, it is generally preferable to avoid hormonal therapy, particularly in women with mild symptoms or at risk for estrogen-responsive neoplasia. Therefore, the most common treatment options are over-the-counter vaginal creams for symptomatic relief. METHODS Thirty-three postmenopausal women suffering from GSM were enrolled in this observational study. A multi-component cream (Ginetrox®, Indena, Milan, Italy) was applied on th…

medicine.medical_specialtyVisual analogue scaleVaginal DiseasesPainmedicine.disease_causeMedication AdherenceInternal medicinemedicineHumansAgedbusiness.industryGenitourinary systemObstetrics and GynecologySyndromeMiddle Agedmedicine.diseaseSymptomatic reliefMenopauseAdministration Intravaginalmedicine.anatomical_structureDyspareuniaTreatment OutcomeTolerabilityItalyVaginaVaginal Creams Foams and JelliesHormonal therapyFemalePlant PreparationsVulvar DiseasesIrritationMenopausebusinessMinerva ginecologica
researchProduct

Changes in Self-Reported Physical Fitness, Performance, and Side Effects Across the Phases of the Menstrual Cycle Among Competitive Endurance Athletes

2019

Purpose: To investigate changes in self-reported physical fitness, performance, and side effects across the menstrual cycle (MC) phases among competitive endurance athletes and to describe their knowledge and communication with coaches about the MC. Methods: The responses of 140 participants (older than 18 y) competing in biathlon or cross-country skiing at the (inter)national level were analyzed. Data were collected via an online questionnaire addressing participants’ competitive level, training volume, MC history, physical fitness, and performance during the MC, MC-related side effects, and knowledge and communication with coaches about the MC and its effects on training and performance. …

medicine.medical_specialtymedia_common.quotation_subjectPhysical fitnessPhysical Therapy Sports Therapy and RehabilitationComputer-assisted web interviewingCoachingsex hormones03 medical and health sciences0302 clinical medicinecoachingPhysical fitness performanceMedicineOrthopedics and Sports MedicineNational levelLack of knowledgetraining quality030212 general & internal medicinevalmennusfemale athleteehkäisymenetelmätMenstrual cyclemedia_commonsukupuolihormonitbiologybusiness.industryAthletes030229 sport sciencesbiology.organism_classificationcoach educationPhysical therapyhormonal contraceptivesbusinessurheilijat
researchProduct

Hypofractionated postoperative helical tomotherapy in prostate cancer: a mono-institutional report of toxicity and clinical outcomes

2018

Francesco Cuccia,1,2 Gianluca Mortellaro,2 Vincenzo Serretta,3 Vito Valenti,1,2 Antonella Tripoli,1,2 Marina Gueci,1,2 Nicoletta Luca,1,2 Antonio Lo Casto,4 Giuseppe Ferrera2 1Radiation Oncology School, University of Palermo, Palermo, Italy; 2Radiation Oncology, ARNAS-Civico Hospital, Palermo, Italy; 3Section of Urology, Department of Surgical Oncological and Oral Science, University of Palermo, Palermo, Italy; 4Radiation Oncology School, Section of Radiological Sciences, DIBIMED, Università degli Studi di Palermo, Palermo, Italy Purpose: This is a mono-institutional study of acute and late toxicities and early biochemical control of a retrospective series of 75 prostate…

medicine.medical_specialtymedicine.medical_treatmentUrologyTomotherapy030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineadjuvantsalvagemedicineradiotherapyOriginal ResearchGenitourinary systembusiness.industryhypofractionationCommon Terminology Criteria for Adverse Eventsmedicine.diseaseRadiation therapyOncologyprostate neoplasmCancer Management and Research030220 oncology & carcinogenesisToxicityHormonal therapyProstate neoplasmbusinessCancer Management and Research
researchProduct

Tubular carcinoma of the breast: Outcome and loco-regional recurrence in 307 patients

2005

Abstract Purpose The aim of this study is to describe the University of Florence experience in evaluating clinical, pathologic and treatment factors as they are related to the outcome and loco-regional recurrence in patients with tubular breast carcinoma. Material and methods Three hundred and seven patients (median age 56.4 years, range 26–91 years) with histological verified tubular carcinoma of the breast were consecutively treated at University of Florence from 1976 to 2001. All patients were followed for a median of 8.4 years (range 3 months to 20 years). Thirty-seven women underwent mastectomy and 270 underwent breast conserving surgery. Positive axillary nodes were found in 15% of pa…

medicine.medical_treatmentDiseaseSegmentalMastectomy SegmentalBreast cancerDuctalBreast-conserving surgery80 and overBreastAdjuvantMastectomyAged 80 and overCarcinoma Ductal BreastTubular carcinomaGeneral MedicineMiddle AgedCombined Modality TherapyTreatment OutcomeBreast cancer; Radiotherapy; Tubular carcinoma; Adenocarcinoma; Adult; Aged; Aged 80 and over; Antineoplastic Agents Hormonal; Axilla; Breast Neoplasms; Carcinoma Ductal Breast; Chemotherapy Adjuvant; Combined Modality Therapy; Female; Humans; Lymphatic Metastasis; Mastectomy; Mastectomy Segmental; Middle Aged; Neoplasm Recurrence Local; Proportional Hazards Models; Radiotherapy Adjuvant; Survival Analysis; Tamoxifen; Treatment Outcome; Oncology; SurgeryLocalOncologyChemotherapy AdjuvantLymphatic MetastasisFemaleMastectomymedicine.drugAdultmedicine.medical_specialtyAntineoplastic Agents HormonalAntineoplastic AgentsBreast NeoplasmsAdenocarcinomaBreast cancermedicineChemotherapyHumansAgedProportional Hazards ModelsChemotherapyRadiotherapyHormonalbusiness.industryCarcinomamedicine.diseaseSurvival AnalysisSurgeryRadiation therapyTamoxifenNeoplasm RecurrenceAxillaRadiotherapy AdjuvantSurgeryTubular carcinomaNeoplasm Recurrence LocalbusinessTamoxifen
researchProduct

Neridronate prevents bone loss in patients receiving androgen deprivation therapy for prostate cancer.

2004

Today, androgen deprivation therapy is a cornerstone of treatment for advanced prostate cancer, although it presents important complications such as osteoporosis. Neridronate, a relatively new bisphosphonate, is able to prevent bone loss in patients with prostate cancer during androgen ablation. Introduction: Androgen-deprivation therapy (ADT) is a cornerstone of treatment for advanced prostate cancer. This therapy has iatrogenic complications, such as osteoporosis. The aim of our study was to evaluate the efficacy of neridronate, a relatively new bisphosphonate, to prevent bone loss during androgen ablation. Materials and Methods: Forty-eight osteoporotic patients with prostate cancer, tre…

musculoskeletal diseasesMalemedicine.medical_specialtyDeoxypyridinolineTime FactorsBicalutamideAntineoplastic Agents HormonalEndocrinology Diabetes and Metabolismmedicine.medical_treatmentOsteoporosisUrologyBone and BonesAndrogen deprivation therapychemistry.chemical_compoundProstate cancerAbsorptiometry PhotonBone DensityMedicineNeridronic acidHumansOrthopedics and Sports MedicineAmino AcidsAgedCholecalciferolTriptorelin PamoateDiphosphonatesbusiness.industryProstatic NeoplasmsAndrogen AntagonistsBisphosphonatemedicine.diseaseAlkaline PhosphataseAndrogen deprivation therapy; Bisphosphonates; Neridronate; Osteoporosis; Prostate cancer; Absorptiometry Photon; Aged; Alkaline Phosphatase; Amino Acids; Androgen Antagonists; Androgens; Antineoplastic Agents Hormonal; Bone Density; Bone and Bones; Calcium; Cholecalciferol; Diphosphonates; Humans; Male; Osteoporosis; Prostatic Neoplasms; Time Factors; Triptorelin Pamoate; SurgerySurgerychemistryAndrogensOsteoporosisCalciumbusinessCholecalciferolmedicine.drugJournal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
researchProduct

COMPliance and Arthralgia in Clinical Therapy: the COMPACT trial, assessing the incidence of arthralgia, and compliance within the first year of adju…

2014

5 Office-based Professional Association Gynecologic Oncologists e.V. in Germany (BNGO e.V.), Berlin; 6 Background: This prospective study evaluated the relationship between arthralgia and compliance during the first year of adjuvant anastrozole therapy in postmenopausal women with hormone receptor-positive early breast cancer. Patients and methods: COMPliance and Arthralgia in Clinical Therapy (COMPACT) was an open-label, multicenter, noninterventional study conducted in Germany. Patients had started adjuvant anastrozole 3-6 months before the study start. The primary end points were arthralgia, compliance, and the relationship between compliance and arthralgia, assessed at specific time poi…

musculoskeletal diseasesmedicine.medical_specialtyAntineoplastic Agents Hormonalmedicine.medical_treatmentSpecific timeAnastrozoleBreast NeoplasmsAnastrozoleMedication AdherenceBreast cancerInternal medicineNitrilesmedicineHumansProspective Studiesskin and connective tissue diseasesProspective cohort studyAgedbusiness.industryDrug SubstitutionIncidence (epidemiology)IncidenceHematologyMiddle AgedTriazolesmedicine.diseaseArthralgiaSurgeryCompliance (physiology)Clinical therapyTreatment OutcomeOncologyChemotherapy AdjuvantFemalebusinessAdjuvantmedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Oxygen uptake, acid-base balance and hormonal responses in maximal 300 - 400 m running in child, adolescent and adult athletes

2013

Vilmi, Nikke (2013). Oxygen uptake, acid-base balance and hormonal responses in maximal 300 - 400 m running in child, adolescent and adult athletes. Department of Biology of Physical Activity, University of Jyväskylä, Master's thesis, Science of Sport Coaching and Fitness Testing, 55 pp. The 400 m sprint demands both aerobic and anaerobic energy systems. During the race the acid-base balance of the body is disturbed and that has effects on the oxygen uptake. The purpose of this study was to investigate the oxygen uptake and acid-base balance during and after the maximal anaerobic running test in child (300 m), adolescent (350 m) and adult (400 m) athletes. Furthermore, the aim was also to d…

oxygen uptakepHjuoksijathormonal responsesLong sprint runningacid-base balancehappo-emästasapaino400 m runjuoksuurheilijathapenotto
researchProduct

Long-term outcome of antiandrogen monotherapy in advanced prostate carcinoma. Twelve-year’s results of a phase II study.

2003

OBJECTIVE: To present the long-term outcome of patients with locally advanced or metastatic prostate carcinoma treated by first-line antiandrogen monotherapy. PATIENTS AND METHODS: From 1983 to 1990, 41 patients with advanced prostate carcinoma were treated with flutamide monotherapy until progression or the appearance of toxicity. Twenty-five patients (61%) had T3-T4N0M0 and 16 (39%) T2-4N0-3M1 prostate carcinoma. Consensus criteria were adopted to evaluate the response. Plasma testosterone and sexual function were recorded for the first 3 years. RESULTS: Flutamide was administered for up to 147 months; seven patients (17%) interrupted the treatment because of toxicity. There was an object…

prostate cancer hormonal therapy antiandrogen flutamideSettore MED/24 - Urologia
researchProduct